A COVID-19 candidate protein subunit vaccine.
Potential treatment - pre-clinical evidence
MVC-COV1901 is a COVID-19 candidate protein subunit vaccine being developed by Medigen Vaccine Biologics Corporation/NIAID/Dynavax. It is based on a prefusion SARS-CoV-2 spike immunogen with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide serving as adjuvants (Kuo et al., 2020). Currently, this COVID-19 candidate vaccine is being evaluated in Phase I and Phase II clinical trials.
S-2P subunit vaccine
|Link||Tested on||Impact factor||Notes||Publication date||DB entry date|
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Protein factor Animal model Mixed substance
|HEK293-hACE2 cells; Vero E6 cells; female BALB/c and C57BL/6 mice; Wuhan-Hu-1 strain SARS-CoV-2 spike protein pseudovirus; live SARS-CoV-2 (hCoV-19/Taiwan/CGMH-CGU-01/2020, GenBank accession MT192759)||
Used with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide as adjuvants, the candidate vaccine induced high titer of neutralizing antibodies against pseudotyped virus or live SARS-CoV-2 in sera of immunized mice. No serious adverse reactions were noted.
|Draft landscape of COVID-19 candidate vaccines||healthy adults||Jul/28/2020||Aug/06/2020|
|ID||Title||Status||Phase||Start date||Completion date|
|NCT05197153||A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19||Not yet recruiting||Phase 2||Jan/01/2022||Dec/01/2022|
|NCT05132855||The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine||Active, not recruiting||Phase 1|Phase 2||Nov/30/2021||Apr/01/2023|
|NCT05011526||A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults||Active, not recruiting||Phase 3||Oct/08/2021||Jun/01/2022|
|NCT05097053||A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19||Recruiting||Phase 4||Oct/07/2021||Jul/01/2022|
|NCT05079633||A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults||Active, not recruiting||Phase 4||Sep/30/2021||Jun/01/2022|
|NCT05054621||Immunogenicity of COVID-19 Vaccine on Heterologous Schedule||Recruiting||Phase 2||Sep/15/2021||Aug/31/2022|
|NCT05038618||A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study||Active, not recruiting||Phase 2||Aug/02/2021||Feb/01/2022|
|NCT04951388||A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents||Active, not recruiting||Phase 2||Jul/22/2021||May/01/2022|
|NCT05048849||A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study||Active, not recruiting||Phase 2||Jul/19/2021||Mar/01/2022|
|NCT04822025||A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults||Active, not recruiting||Phase 2||May/20/2021||Jan/01/2022|
|NCT04695652||A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult||Active, not recruiting||Phase 2||Dec/30/2020||Jun/01/2022|
|NCT04487210||A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19||Active, not recruiting||Phase 1||Oct/07/2020||Dec/30/2021|